Detect and localize with Axumin

Find prostate cancer across local and distant sites of recurrence

Find an Axumin Imaging Center
View Featured Case Study
Order Axumin

4+ Years

Over 100,000 Doses Administered

At Blue Earth Diagnostics, we develop and provide PET diagnostic imaging radiopharmaceutical products to inform diagnosis and treatment decisions for patients with recurrent prostate cancer. We stand committed to supporting those parts of life that matter most: health and well-being.

September marks Prostate Cancer Awareness Month, a time for raising awareness and taking action to help fight this serious disease that takes the lives of approximately 33,330 U.S. men each year.1

Blue Earth Diagnostics has a strong commitment in prostate cancer, and we are driven to find innovative imaging solutions for men affected by this disease. We work closely with physicians, healthcare professionals and patients to provide access to PET imaging products that can help guide decisions about patient care. Our initial product, Axumin® (fluciclovine F 18) injection, is FDA-approved for PET imaging of prostate cancer recurrence and widely available across the U.S.

At our core, Blue Earth Diagnostics is all about helping patients. We continue to work tirelessly toward that goal so that more men with recurrent prostate cancer can benefit from informed decision making resulting from advanced diagnostic imaging.

1https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html; accessed August 10, 2020

U.S. Imaging Centers may obtain Axumin exclusively via Siemens’ PETNET Solutions. To order, please call their Customer Care line at 1-877-473-8638.

INDICATION

Axumin® (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

  • Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
  • Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
  • Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
  • Adverse reactions were reported in ≤1% of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Axumin full Prescribing Information.

You are now leaving Axumin.com. Do you wish to proceed?

Yes, proceed.
No, take me back to Axumin.com